The FDA on August 16, 2018 granted accelerated approval to OPDIVO® for patients with metastatic Small Cell Lung Cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. OPDIVO® is a product of Bristol-Myers Squibb Company Inc.
Bottom Ad
Advertisement
Subscribe
